Massimo Aglietta

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Thierry André, Sara Lonardi, Ka Yeung Mark Wong et al. · Annals of Oncology · 2022 · 253 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO

Daniele Rossini, Carlotta Antoniotti, Sara Lonardi et al. · Journal of Clinical Oncology · 2022 · 78 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.

Heinz‐Josef Lenz, Sara Lonardi, Vittorina Zagonel et al. · Journal of Clinical Oncology · 2020 · 60 citations

Medicine, Oncology, Pharmacotherapy +17

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2019 · 39 citations

Medicine, Oncology, Pharmacotherapy +14